HK Stock MarketDetailed Quotes

09969 INNOCARE

Watchlist
  • 6.430
  • -0.050-0.77%
Market Closed Dec 12 16:08 CST
11.33BMarket Cap-27.25P/E (TTM)

About INNOCARE Company

The company is a commercialized biomedical high-tech company. It was co-founded in 2015 by Dr. Cui Jisong, who has extensive experience in new drug development and enterprise management, and Academician Shi Yigong, a world-famous structural biologist. We develop innovative drugs for patients with malignant tumors and autoimmune diseases, so that innovative results can benefit more patients. The company is a high-tech innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D, production and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and develops first-of-its-kind or best-in-class drugs with breakthrough potential in the global market. Main products: obutinib, ICP-B04, ICP-248, ICP-B02, ICP-490, ICP-B05, ICP-332, ICP-488, ICP-B02, ICP-923, ICP-723,, ICP-192, etc. ICP-189

Company Profile

Symbol09969
Company NameINNOCARE
ISINKYG4783B1032
Listing DateMar 23, 2020
Issue Price8.95
Shares Offered250.32M share(s)
FoundedNov 3, 2015
Registered AddressCayman Islands
Chairmanjisong cui
Secretaryxiepeishan li
Audit InstitutionErnst & Young, Ernst & Young Huaming
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeOgier Global (Cayman) Limited's offices 89 Nexus Way Camana Bay Grand Cayman, KY1-9009 Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees1109
MarketHong Kong motherboard
Phone(86)1066609999
Fax(86)1060702992
Emailinfo@innocarepharma.com
Websitehttp://www.innocarepharma.com
BusinessNuochengjianhua is an innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and develops best-in-class or first-of-its-kind drugs with breakthrough potential in the global market.

Company Executives

  • Name
  • Position
  • Salary
  • jisong cui
  • Presidencies, CEO, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Authorized Representative
  • --
  • renbin zhao
  • Executive Director
  • --
  • yigong shi
  • Non-executive Directors
  • --
  • dandan dong
  • Independent Non-Executive Director, Audit Committee Members, Remuneration Committee Members, Nomination Committee Members
  • 80.00K
  • ronggang xie
  • Non-executive Directors, Audit Committee Members
  • --
  • lan hu
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Chairman, Nomination Committee Members
  • --
  • xin fu
  • Chief Financial Officer
  • --
  • xiangyang zhang
  • Chief Medical Officer
  • --
  • xiangyang chen
  • Chief Technology Officer
  • --
  • xiepeishan li
  • Authorized Representative, Company Secretary
  • --
Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Biotechnology
Biotechnology
Intraday-1.09%